Krystal Biotech, Inc. cash flow to debt ratio of 2.15K% indicates that the company generates enough cash to cover a substantial portion of its debt. This level indicates very strong financial health.

Krystal Biotech, Inc.'s free cash flow has increased 58.51% from $119.18M last year to $188.91M, signaling increasing performance

Krystal Biotech, Inc.'s debt to equity ratio is 0.01, which means that the company's assets are healthy financed, signaling financial stability.

Krystal Biotech, Inc.'s debt has increased relative to shareholder equity from 0.01 last year to 0.01 today, signaling weakened financials

Krystal Biotech, Inc. has a net cash position, so leverage is healthy.

Krystal Biotech, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Krystal Biotech, Inc.'s profit margin has increased (78.62%) in the last year from 30.69% to 54.82%, signaling increasing performance

Krystal Biotech, Inc.'s short-term assets of $1.02B exceed its short-term liabilities of $102.94M

Krystal Biotech, Inc.'s return on assets of 16.09% is higher than the 5.00% threshold, indicating efficient asset utilization

Krystal Biotech, Inc.'s return on equity of 19.34%, is higher than 15.00%, indicating good performance

Krystal Biotech, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Krystal Biotech, Inc. had positive net income in 3 out of 5 years, indicating stable and consistent earnings

Krystal Biotech, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

Krystal Biotech, Inc. has a free cash flow yield of 1.93%, which is below the 2.00% threshold, indicating limited cash return relative to market value

Krystal Biotech, Inc.'s yearly earnings has increased 129.74% since last year from $89.16M to $204.83M, signaling increasing performance

Krystal Biotech, Inc.'s yearly revenue has increased 33.94% since last year from $290.51M to $389.13M, signaling increasing performance

ROIC 14.39% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.

Krystal Biotech, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Krystal Biotech, Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Krystal Biotech, Inc. had positive ROE in 3 out of 5 years, indicating consistent and reliable returns on equity

Krystal Biotech, Inc. has insufficient data to evaluate this check.

Krystal Biotech, Inc. has an earnings yield of 2.47%, which is below the 4.00% threshold, indicating the stock may be expensive relative to its earnings

Krystal Biotech, Inc. is overvalued relative to its fair value price of 56.86 based on EBITDA multiple model

Krystal Biotech, Inc. has an EV/EBITDA ratio of 45.69x, which exceeds the 20.00x threshold, indicating the stock may be overvalued relative to its operating earnings

Krystal Biotech, Inc. has insufficient data to evaluate this check.

Krystal Biotech, Inc. had non-positive diluted EPS five years ago; the PEG ratio is not meaningful and the check fails.

Krystal Biotech, Inc. has a price-to-book ratio of 7.20x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Krystal Biotech, Inc. has a price-to-sales ratio of 22.23x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue